The global travel vaccines market reached a value of US$ 3.2 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 6.6 Billion by 2027, exhibiting a CAGR of 11.1% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Travel vaccines, also known as travel immunizations, are vaccines travelers can get before they visit certain regions across the globe which help protect them from serious diseases. Travel vaccines work by exposing the body to a microorganism or parts of the microorganism of the disease it will protect against. The body responds to the vaccination by making antibodies that will protect it against a situation where there is an exposure to the disease in the future. The number of international tourist arrivals worldwide increased from 1.0 Billion in 2012 to nearly 1.4 Billion in 2018. A significant number of these travelers journey from developed countries to regions with endemic diseases. As more people travel to countries with endemic diseases, the demand for vaccines will continue to increase. Moreover, regulatory authorities across the globe have also mandated that travelers should be vaccinated before traveling to disease-prone regions. As a result, travel vaccines have now become an essential requirement in an international travelers list. For instance, the Ministry of Health in the Kingdom of Saudi Arabia requires that all travelers arriving for Hajj and Umrah from countries or areas at risk of diseases such as yellow fever, Meningococcal meningitis and Poliomyelitis must present a valid vaccination certificate. Other factors driving the demand for travel vaccines include increasing awareness levels, technological advancements and increasing incidence of life-threatening infectious diseases.
Combination vaccines currently account for the majority of the market share as they are given to travelers in order to protect against multiple diseases.
Amongst these, hepatitis A represents the largest disease, dominating the market. It is a viral disease that can be transmitted through direct contact with an infectious person or the consumption of contaminated food and water.
On the geographical front, North America enjoys the leading position in the market. A large number of companies in the region are introducing a superior range of travel vaccines, including a vaccine against varicella.
2. What will be the travel vaccines market outlook during the forecast period (2022-2027)?
3. What are the global travel vaccines market drivers?
4. What are the major trends in the global travel vaccines market?
5. What is the impact of COVID-19 on the global travel vaccines market?
6. What is the global travel vaccines market breakup by composition?
7. What is the global travel vaccines market breakup by disease?
8. What are the major regions in the global travel vaccines market?
9. Who are the leading travel vaccines market players?
Travel vaccines, also known as travel immunizations, are vaccines travelers can get before they visit certain regions across the globe which help protect them from serious diseases. Travel vaccines work by exposing the body to a microorganism or parts of the microorganism of the disease it will protect against. The body responds to the vaccination by making antibodies that will protect it against a situation where there is an exposure to the disease in the future. The number of international tourist arrivals worldwide increased from 1.0 Billion in 2012 to nearly 1.4 Billion in 2018. A significant number of these travelers journey from developed countries to regions with endemic diseases. As more people travel to countries with endemic diseases, the demand for vaccines will continue to increase. Moreover, regulatory authorities across the globe have also mandated that travelers should be vaccinated before traveling to disease-prone regions. As a result, travel vaccines have now become an essential requirement in an international travelers list. For instance, the Ministry of Health in the Kingdom of Saudi Arabia requires that all travelers arriving for Hajj and Umrah from countries or areas at risk of diseases such as yellow fever, Meningococcal meningitis and Poliomyelitis must present a valid vaccination certificate. Other factors driving the demand for travel vaccines include increasing awareness levels, technological advancements and increasing incidence of life-threatening infectious diseases.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global travel vaccines market, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on composition and disease.Breakup by Composition:
- Mono Vaccines
- Combination Vaccines
Combination vaccines currently account for the majority of the market share as they are given to travelers in order to protect against multiple diseases.
Breakup by Disease:
- Hepatitis A
- DPT
- Yellow Fever
- Typhoid
- Hepatitis B
- Measles and Mumps
- Rabies
- Meningococcal
- Varicella
- Japanese Encephalitis
- Others
Amongst these, hepatitis A represents the largest disease, dominating the market. It is a viral disease that can be transmitted through direct contact with an infectious person or the consumption of contaminated food and water.
Regional Insights:
- Asia Pacific
- North America
- Europe
- Middle East and Africa
- Latin America
On the geographical front, North America enjoys the leading position in the market. A large number of companies in the region are introducing a superior range of travel vaccines, including a vaccine against varicella.
Competitive Landscape:
The market is concentrated in nature with the presence of a handful of manufacturers who compete in terms of prices and quality. Some of the leading players operating in the market are:
- GlaxoSmithKline Pharmaceuticals Limited
- Sanofi Pasteur
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- ALK-Abelló A/S
- Bavarian Nordic A/S
- Crucell (Subsidiary of Johnson & Johnson)
- CSL Limited
- AstraZeneca PLC
- Altimmune, Inc.
- Abbott Laboratories
- Hoffmann-La Roche, Inc.
Key Questions Answered in this Report
1. What was the global travel vaccines market size in 2021?2. What will be the travel vaccines market outlook during the forecast period (2022-2027)?
3. What are the global travel vaccines market drivers?
4. What are the major trends in the global travel vaccines market?
5. What is the impact of COVID-19 on the global travel vaccines market?
6. What is the global travel vaccines market breakup by composition?
7. What is the global travel vaccines market breakup by disease?
8. What are the major regions in the global travel vaccines market?
9. Who are the leading travel vaccines market players?
Frequently Asked Questions about the Global Travel Vaccines Market
What is the estimated value of the Global Travel Vaccines Market?
What is the growth rate of the Global Travel Vaccines Market?
What is the forecasted size of the Global Travel Vaccines Market?
Who are the key companies in the Global Travel Vaccines Market?
| Report Attribute | Details |
|---|---|
| No. of Pages | 107 |
| Published | February 2022 |
| Forecast Period | 2021 - 2027 |
| Estimated Market Value ( USD | $ 3.2 Billion |
| Forecasted Market Value ( USD | $ 6.6 Billion |
| Compound Annual Growth Rate | 12.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
Table of Contents
1 Preface3 Executive Summary12 Global Travel Vaccines Industry: Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Travel Vaccines Market
6 Market Breakup by Composition
7 Market Breakup by Disease
8 Market Breakup by Region
9 Global Travel Vaccines Industry: SWOT Analysis
10 Global Travel Vaccines Industry: Value Chain Analysis
11 Global Travel Vaccines Industry: Porters Five Forces Analysis
13 Travel Vaccines Manufacturing Process
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- GlaxoSmithKline Pharmaceuticals Limited
- Sanofi Pasteur
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- ALK-Abelló A/S
- Bavarian Nordic A/S
- Crucell (Subsidiary of Johnson & Johnson)
- CSL Limited
- AstraZeneca PLC
- Altimmune, Inc.
- Abbott Laboratories
- Hoffmann-La Roche, Inc.
Methodology
LOADING...
